Blood drawn at registry sites is banked for by scientists affiliated with LMRI. Study Objectives: The Lowy Medical Research Institute is to determine if MacTel has a genetic component. in the registry involves an initial clinic visit with a comprehensive eye exam, and blood is drawn for MacTel research. Pathology: Macular Telangiectasia type 2 (MacTel 2)ĭescription: World-wide registry of individuals with Macular Telangiectasia type 2, and their family members. NHOR (Natural History Observation Registry) Study Objectives: Change in GA lesion growth of eyes treated with JNJ-81201887 compared to sham control: Change in square root GA lesion area in the study eye measured on FAF. Study Objectives: To better understand the optimal timing of surgical intervention for the best visual result, quantify metamorphopsia, and evaluate post surgical progression of ERM.ĭescription: A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD). Study Objectives: Verify and characterize abnormally expressed vitreous proteins in adults with full thickness macular holes (MH) versus vitreous from a floaterectomy control group.ĭescription: Randomized Trial Comparing Immediate versus Deferred Surgery for Symptomatic Epiretinal Membranes Despite improved glycemic control for many patients, Diabetic Retinopathy progresses in a large majority of patientsĭescription: Vitreous Proteomics in Eyes with a Macular Hole Study Objectives: To assess the ability of oral Fenofibrate to prevent progression of Diabetic Retinopathy in an at risk population (mild to moderately-severe NPDR). Pathology: Non-Proliferative Diabetic Retinopathy (NPDR)ĭescription: A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening Study Objectives: To determine the efficacy of intravitreal 2.0 mg OPT-302 when administered in combination with intravitreal 2.0 mg aflibercept, in participants with neovascular AMD Pathology: Neovascular Age-Related Macular Degeneration (nAMD)ĭescription: A Phase 3, multicentre, double-masked, randomized study to evaluate the efficacy and safety of intravitreal OPT-302 in combination with aflibercept, between changes in retina function with the severity of diabetic retinopathy. Study Objectives: The primary objective is to evaluate the safety and tolerability of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD. Pathology: Wet Age-Related Macular Degeneration (AMD)ĭescription: A Phase 1, Multicenter, Open-Label, Single- and Multi-Dose, Dose-Escalating Clinical Study to Evaluate the Safety and Tolerability of OLX10212 Administered by Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration Study Objectives: To evaluate the efficacy of QA102 oral capsules on the development/progression of geographic atrophy and/or development of CNV in patients with intermediate to small lesion advanced dry AMD. Pathology: High Risk Intermediate Age-Related Macular Degeneration (AMD) or Small Lesion Geographic Atrophy (GA)ĭescription: A Phase 2, Double-Masked, Randomized, Placebo-Controlled, Dose-Response Study Assessing the Safety and Efficacy of AQ102 in Subjects with dry AMD
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |